摘要
目的观察舒肝解郁胶囊联合米氮平治疗抑郁症的疗效和安全性。方法将57例抑郁症患者分为两组,研究组30例用舒肝解郁胶囊联合米氮平治疗,对照组27例单用米氮平。采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和不良反应量表(TESS)分别观察疗效和不良反应,连续观察6周。结果治疗第1周,两组HAMD和HAMA评分均下降,差异有统计学意义(P<0.01)。第2周末开始两组间HAMD和HAMA评分差异无统计学意义。第6周末两组显效率分别为83.33%和81.48%,差异无统计学意义(P>0.05)。两组间TESS评分每周差异无统计学意义(P>0.05)。结论舒肝解郁联合米氮平治疗抑郁症起效快,患者的满意度和依从性好。
Objective To observe the effect and safety of combination treatment of Shugan Jieyu Capsule plus mirtazapine on treating depres- sion. Methods 57 cases of depression were divided into two groups,the study group（30 cases） treated with combination of Shugan Jieyu Cap- sule and mirtazapine and the control group（27 cases） treated with mirtazapine alone. The Hamilton Depression Rating Scale（HAMD）, the Hamihon Anxiety Scale（HAMA） and the Side Effects Scale（TESS） were used to continuously observe the effectiveness and adverse reactions for 6 weeks. Results In 1 week,the HAMD and HAMA scores were decreased in both groups with statistical difference between them （P 〈 0. 01）. After the second weekend,there were no significant differences in HAMD and HAMA scores between the two groups. At the sixth weekend,the markedly effective rate of the two groups were 83.33% and 81.48% respectively,without statistical differences（ P 〉 0.05）. And there were no remarkable differences in TESS scores at each weekend between the two groups. Conclusion Shugan Jieyu Capsule combined with mirtazapine in the treatment of depression has faster and greater effectiveness with better patients＇ satisfaction and better compliance.
出处
《中国药业》
CAS
2012年第20期102-103,共2页
China Pharmaceuticals
关键词
舒肝解郁胶囊
米氮平
抑郁症
Shugan Jieyu Capsule
mirtazapine
depression
